1420 - Extracorporeal photopheresis for treatment of acute and chronic graft-versus-host disease and cutaneous T-cell lymphoma

Page last updated: 29 September 2017

Application Detail



Description of Medical Service

Extracorporeal photopheresis (ECP) service is indicated for the management of steroids-refractory acute and chronic GVHD and CTCL. It is a cell-based immunomodulatory therapy performed via intravenous access, comprising three stages: leukapheresis, photoactivation and reinfusion. Blood is passed through multiple cycles of leukapheresis. At the end of the each leukapheresis cycle, the red blood cells and plasma are returned to the patient. Only a small percentage (approximately 10%) of leukocytes is collected from peripheral blood. These white blood cells are incubated with a photosensitising agent, methoxsalen (UVADEX®), and are then exposed to ultraviolet A (UVA) irradiation, after which the treated cells are reinfused back to the patient.

Description of Medical Condition

Graft-versus-host disease Graft-versus-host disease (GVHD) is an immune-mediated disease resulting from a complex interaction between donor and recipient adaptive immunity. It is a frequent complication of allogeneic bone marrow transplants or solid organ transplants.

Reason for Application

New MBS item

Medical Service Type


Previous Application Number

Not Applicable

Associated Documentation

Application Form


PICO Confirmation

Two protocols are being developed for this MSAC application:

1) Extracoporeal photopheresis for treatment of acute and chronic graft-versus-host disease:
1420 GVHD - Consultation Protocol (PDF 1774 KB)
1420 GVHD - Consultation Protocol (Word 506 KB)

2) Extracoporeal photopheresis for treatment of cutaneous T-cell lymphoma:
1420 Final Protocol (PDF 1791 KB)
1420 Final Protocol (Word 850 KB)

Assessment Report


Public Summary Document

Public Summary Document (PDF 361 KB)
Public Summary Document (Word 130 KB)

Meetings for this Application


11 - 12 August 2016


8 June 2017


27 July 2017